$AST new volume recovery $3.88 AMEX Interim Ef
Post# of 46
Posted On: 09/10/2016 6:12:27 PM
$AST new volume recovery $3.88
AMEX
Interim Efficacy Data from SCiStar Clinical Trial
of AST-OPC1 in Complete Cervical Spinal Cord Injury
Website
Low Float
Shares Outstanding 45.42M
Float 16.45M
% Held by Insiders 69.33%
% Held by Institutions 11.30%
Shares Short 1.13M
Short Ratio 12.36
Short % of Float 6.68%
Shares Short (prior month) 1.15M
Headlines
and Filings
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. It is developing AST-VAC1, an autologous product candidate that completed Phase II clinical trialS for the treatment of acute myelogenous leukemia; AST-VAC2, an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase that is in pre-clinical stage; and AST-OPC1, which is in Phase I/IIa clinical trials for the treatment of spinal cord injury, multiple sclerosis, and stroke. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.
AMEX
Interim Efficacy Data from SCiStar Clinical Trial
of AST-OPC1 in Complete Cervical Spinal Cord Injury
Website
Low Float
Shares Outstanding 45.42M
Float 16.45M
% Held by Insiders 69.33%
% Held by Institutions 11.30%
Shares Short 1.13M
Short Ratio 12.36
Short % of Float 6.68%
Shares Short (prior month) 1.15M
Headlines
and Filings
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. It is developing AST-VAC1, an autologous product candidate that completed Phase II clinical trialS for the treatment of acute myelogenous leukemia; AST-VAC2, an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase that is in pre-clinical stage; and AST-OPC1, which is in Phase I/IIa clinical trials for the treatment of spinal cord injury, multiple sclerosis, and stroke. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.
(0)
(0)